HUTCHMED (China) Limited (AIM: HCM)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 1.94B |
| Revenue (ttm) | 483.31M |
| Net Income (ttm) | -33.21M |
| Shares Out | 854.68M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,897 |
| Average Volume | 49,452 |
| Open | 236.00 |
| Previous Close | 234.00 |
| Day's Range | 223.00 - 236.00 |
| 52-Week Range | 190.40 - 353.00 |
| Beta | 0.76 |
| RSI | 40.09 |
| Earnings Date | Mar 5, 2025 |
About HUTCHMED (China)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, an... [Read more]
News
HUTCHMED (China) Ltd (HCM) Shares Gap Down to $13.87 on Jan 15
HUTCHMED (China) Ltd (HCM) Shares Gap Down to $13.87 on Jan 15
Hutchmed (HCM) Shares Drop Over 5.7% Amid Delayed Approvals
Hutchmed (HCM) Shares Drop Over 5.7% Amid Delayed Approvals
HUTCHMED (China) Ltd (HCM) Gains Full Approval for ORPATHYS® in China
HUTCHMED (China) Ltd (HCM) Gains Full Approval for ORPATHYS® in China
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
— Indication expands to include treatment-naïve patients — — The 2021 conditional approval in previously treated patients converted to full approval — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Ja...
Chinese regulators accept NDA for Orpathys/Tagrisso combo
Chinese regulators have accepted HUTCHMED's (HCM) application for priority review for the drug combination Orpathys and Tagrisso for the treatment of EGFR-positive lung cancer.
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
On Wednesday, Hutchmed (China) Limited (NASDAQ: HCM) entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately $608 million ...
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
On Wednesday, Hutchmed (China) Limited HCM entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately $608 million (RMB 4.478 ...
Hutchmed sells stake in unit
Biopharmaceutical firm Hutchmed China Ltd., backed by Hong Kong billionaire Li Ka-shing, saw its shares rally on Thursday morning after announcing it will divest shares in a joint venture for about $6...
HUTCHMED divests $608 million in non-core assets
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) f...
Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales
Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the billionaire and his flagship conglomerate look to ramp up capital and pivo...
HUTCHMED to divest 45% stake in JV with Shanghai Pharma
HUTCHMED (China) Ltd (HCM) Announces Strategic Divestment to Focus on Core Innovations
HUTCHMED (China) Ltd (HCM) Announces Strategic Divestment to Focus on Core Innovations
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally —
HUTCHMED (China) Ltd (HCM) Secures $10 Million Milestone Payment Following European ...
HUTCHMED (China) Ltd (HCM) Secures $10 Million Milestone Payment Following European Reimbursement Approval
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA ® (fruquintinib), the first novel oral targeted therapy...
HUTCHMED (China) Ltd (HCM) Receives Breakthrough Therapy Designation for Lung Cancer Treatment
HUTCHMED (China) Ltd (HCM) Receives Breakthrough Therapy Designation for Lung Cancer Treatment
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of ...
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
SAN FRANCISCO, U.S. and SUZHOU, China , Dec. 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commer...
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer
— First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China)...
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal w...
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several reg...
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu ...
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovlep...
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer — — US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer —